Introduction {#S1}
============

Obstructive sleep apnea (OSA) syndrome is caused by repetitive closure of the pharynx during sleep. Although continuous positive airway pressure (CPAP) has been accepted as the standard treatment for moderate to severe OSA ([@B1]), many patients report discomfort or cannot tolerate it. Some of the common side effects such as air leaks, mask discomfort, or aerophagia are related to the pressure level applied ([@B2]). Therefore, any means allowing a reduction of the pressure level without jeopardizing the primary CPAP function might improve patients' comfort and, possibly, treatment adherence.

The collapse of the upper airway in OSA is mainly due to a failure of the pharyngeal dilator muscles to counteract the negative intraluminal pressure generated by the inspiratory muscles. During wakefulness, the pharynx is kept opened by tonic and phasic activations of the dilator muscles during the breathing cycle. These muscles are also activated by a reflex (the "pharyngeal dilators reflex") triggered by mechanoreceptors located in the pharynx and larynx, responding to intraluminal negative pressure. In OSA patients, many abnormalities have been described in the neuromuscular control of the upper airway, including histological evidence of denervation, decreased sensitivity to vibrations and temperature, and EMG evidence of motor neuropathy ([@B3]).

Therefore, dilator muscles are an interesting target in OSA treatment and studies investigating oropharyngeal muscle training by exercises ([@B4]), or direct stimulation ([@B5]--[@B7]), have shown a positive impact on respiratory events.

In an animal study, Plowman et al. demonstrated that high-frequency--low-pressure oscillations delivered to the upper airway of dogs could trigger an augmentation of the genioglossus (GG) electromyographic activity, both during wakefulness and sleep ([@B8]). In a human physiological study, Henke and Sullivan showed that intermittent high-frequency--low-amplitude pressure oscillations also had a stimulating effect on the upper airway muscle tone ([@B9]). When applied to single breaths in sleeping subjects, this oscillating pressure induced a significant activation of the GG muscle and an increase in tidal volume in controls and OSA patients.

Based on these physiological studies, an experimental device was developed (the oscillating positive airway pressure, or "O-PAP") to deliver pressure oscillations superimposed onto CPAP therapy. As it was unclear whether these pressure oscillations could be tolerated during sleep, we designed this study to assess sleep quality under O-PAP, compared to CPAP.

Subjects and Methods {#S2}
====================

Participants {#S2-1}
------------

Subjects were recruited among CPAP-treated OSA outpatients followed at the Center for Investigation and Research in Sleep (Lausanne, Switzerland). Inclusion criteria were \>18 years of age, initial apnea--hypopnea index (AHI) \>15/h, good tolerance to CPAP, mean use of CPAP of \>4 h/night in the last 3 months, and residual AHI on CPAP \<10/h. Exclusion criteria were sleep-related disorders other than OSA, any other disorder disturbing sleep, use of opiates, benzodiazepines, and muscle relaxants, unstable cardiovascular disease, and inability to consent.

Design and set-up {#S2-2}
-----------------

All participants underwent two supervised full polysomnographies, one with CPAP only and one with O-PAP. They were randomized in blocks of four to receive CPAP or O-PAP first. During the first night, a CPAP titration was performed, starting in the first NREM2 period, using an initial pressure of 4 cmH~2~O and increasing by steps of 1 cmH~2~O until control of apneas and hypopneas was achieved. Seventy percent of this optimal pressure was then applied during both polysomnographies. The titration time was not included in the analyses.

Pressure oscillations were administered using a custom-made pressure oscillator connected to the CPAP through a "Y" tubing (Figures [1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}). The oscillations' amplitude was fixed (1 cmH~2~O) and the frequency was titrated by the technician while the patient was awake, starting with 15 Hz, until the patient perceived the vibrations in his throat and not his mouth or thorax.

![**The O-PAP setting**. The pressure oscillation generator (a) and the CPAP (b) are connected to the patient's mask through a "Y" tubing (c). Modified from Wikimedia Commons.](fmed-02-00029-g001){#F1}

![**Schematic drawing of O-PAP in a patient with fixed 8 cmH~2~O CPAP: the O-PAP produces 1 cmH~2~O pressure oscillations (blue line) that are superimposed onto the pressure generated by the CPAP (red line)**. PAW, airway pressure.](fmed-02-00029-g002){#F2}

The polysomnographies were performed using an Embla N7000™ and analyzed with the Somnologica™ software (Embla Systems, Inc., Broomfield, CO, USA). One investigator blinded to treatment modality scored sleep stages according to the American Academy of Sleep Medicine (AASM) 2007 recommendations ([@B10]), and respiratory events using the criteria from the AASM update published in 2012 ([@B11]).

The main study endpoints were total sleep time, arousals index, respiratory arousals index, sleep efficiency, and the Leeds sleep evaluation questionnaire (LSEQ) ([@B12]). The secondary endpoints were the residual AHI under a suboptimal pressure (70% of the optimal titrated pressure), the AHI according to the body position and the sleep stages, and the oxygen desaturation index (ODI) ≥3%.

Statistics {#S2-3}
----------

Sample size was estimated empirically, as there was no data available on the effect of O-PAP on sleep quality. We estimated that we needed to include 12 patients to have an 80% power to detect a difference of 5% in sleep efficiency with a SD of 6% (1 − β = 0.8, α = 0.05). Statistical analysis was made using Medcalc statistical software (MedCalc Software, 8400, Ostend, Belgium). Results are reported as mean ± SD, or median ± interquartile range (IQR). To compare different outcomes between CPAP and O-PAP, we used paired *t*-tests for normally distributed data and Wilcoxon tests for non-normally distributed data.

The study was approved by the local ethics committee (protocol 296/12) and all patients gave written informed consent.

Results {#S3}
=======

Fourteen subjects were included in the study. Their characteristics are shown in Table [1](#T1){ref-type="table"}. Seventy-one percent of them were obese (BMI \>30 kg/m^2^) and all but one had severe OSA (AHI \>30/h). The median pressure applied during both nights (\~70% of titrated pressure) was 6.0 \[4.3--9.8\] cmH~2~O. The mean oscillation frequency applied was 27.1 ± 6.9 Hz.

###### 

**Patients' characteristics**.

                                                                Mean   SD
  ------------------------------------------------------------- ------ -------
  Age (years)                                                   59.9   ±10.1
  BMI (kg/m^2^)                                                 34.8   ±7.2
  Sex M/F (*N*)                                                 13/1   
  Neck circumference (cm)                                       45.0   ±4.4
  Initial AHI (events/h)                                        58.7   ±25.2
  CPAP use (years)                                              4.1    ±1.8
  CPAP pressure[^a^](#tfnT1_1){ref-type="table-fn"} (cmH~2~O)   12.3   ±2.9
  Type of mask (N/FF)                                           6/8    
  aCPAP/CPAP, N                                                 12/2   

*^a^Fixed pressure or pressure at 95th percentile for aCPAP*.

*N, nasal; FF, full face; aCPAP, autoadjusted CPAP*.

Comparison of the respiratory and sleep parameters under both conditions is shown in Table [2](#T2){ref-type="table"}. Sleep quality parameters (arousal index, respiratory arousals index, sleep time, and sleep efficiency) and the perceived sleep quality assessed by the LSEQ were not altered by O-PAP. There was a trend toward a decrease in AHI and ODI with O-PAP compared to CPAP alone, especially in NREM sleep and in the supine position, but none of these differences reached statistical significance.

###### 

**Objective and subjective sleep quality parameters and residual AHI with O-PAP and CPAP under a pressure corresponding to 70% of the optimal CPAP pressure**.

                                                         CPAP                     O-PAP                    *p*
  ------------------------------------------------------ ------------------------ ------------------------ -------
  Arousal index (/h)                                     32.5 \[23.7--44.4\]      28.1 \[22.5--34.7\]      0.296
  Respiratory arousals index (/h)                        16.2 \[11.0--21.2\]      11.5 \[5.4--20.8\]       0.104
  Sleep time[^a^](#tfnT2_2){ref-type="table-fn"} (min)   356.6 \[232.8--390.2\]   336.6 \[234.5--361.0\]   0.325
  Sleep efficiency (%)                                   90.0 \[78.0--92.5\]      88.1 \[71.9--92.6\]      0.542
  Sleep quality VAS (mm)                                 78.8 \[60.6--85.7\]      75.5 \[57.4--85.4\]      0.695
  AHI (/h)                                               20.5 \[13.7--28.9\]      14.3 \[8.5--25.8\]       0.194
  AHI supine (/h)                                        36.9 \[24.0--58.4\]      23.6 \[11.5--66.8\]      0.432
  AHI non-supine (/h)                                    11.7 \[4.5--16.9\]       12.3 \[4.4--21.9\]       0.966
  AHI in REM sleep (/h)                                  7.9 \[5.2--13.6\]        12.6 \[9.1--26.7\]       0.426
  AHI in NREM sleep (/h)                                 22.4 \[13.7--30.9\]      13.2 \[8.2--22.2\]       0.104
  ODI ≥3% (/h)                                           16.2 \[9.9--35.6\]       12.7 \[9.4--22.1\]       0.583

*^a^Sleep time does not include titration*.

*REM, rapid eye movement sleep; NREM, non-rapid eye movement sleep; VAS, visual analog scale*.

*Maximum score 100 mm. Higher score indicates better sleep quality*.

*Results are expressed as median and interquartile range*.

Discussion {#S4}
==========

The main finding of this study is that O-PAP is well tolerated and does not alter objective nor subjective sleep quality in OSA patients. This suggests that the 1 cmH~2~O pressure oscillations applied with O-PAP do not disturb sleep, even when used during the whole night in OSA patients.

As shown by Plowman et al. ([@B8]), pressure oscillations delivered to the upper airway of dogs can trigger an increase in GG EMG activity. In a human physiological study, Henke and Sullivan showed that intermittent pressure oscillations also had a stimulating effect on the upper airway muscle tone ([@B9]). It is thus possible that the constant oscillations generated by the O-PAP could stimulate GG activity and decrease the CPAP pressure required to prevent upper airway collapse and improve the patient's tolerance to the treatment. Even though our sample was not large enough to determine the effect of continuous oscillations on the AHI, we found an interesting trend toward a decrease in the residual AHI compared to standard CPAP under subtherapeutic pressure. These preliminary results should stimulate further research on the effects of O-PAP in OSA patients.

In our study, O-PAP seems to have a greater effect in the supine position and in NREM sleep but not in non-supine position and in REM sleep. This may be due to an altered GG responsiveness since a lower GG activation in response to negative pharyngeal pressure was previously reported in non-supine positions ([@B13]) and in REM sleep ([@B14]). We can also anticipate that O-PAP could be more efficient in younger patients with preserved pharyngeal sensitivity to air vibration since long-term snoring and sleep apnea are associated with altered pharyngeal sensitivity ([@B15]), probably due to sensitive nerve injuries. To determine whether O-PAP could allow treating OSA with lower pressures than CPAP, larger studies including pharyngeal sensitivity measurements and fine CPAP/O-PAP titrations are required.

Our study has a few limitations. First, due to the easily perceived O-PAP vibrations, patients or PSG technician blinding was not feasible. However, the investigator interpreting the polysomnographies was blinded to treatment allocation. Second, our sample size was small. Finally, because the study was powered to find a difference in sleep efficiency, it did not have enough power to detect a significant effect difference between O-PAP and regular CPAP on AHI.

In conclusion, O-PAP seems to be a safe and well-tolerated therapy that does not affect subjective nor objective sleep quality. The positive trend we found toward a reduction in residual AHI with O-PAP should stimulate further research with larger groups of patients to better determine if O-PAP could control OSA with lower pressure than standard CPAP.
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